These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
482 related articles for article (PubMed ID: 32223357)
1. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357 [No Abstract] [Full Text] [Related]
2. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC. Frampton JE Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816 [TBL] [Abstract][Full Text] [Related]
3. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC; Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015 [TBL] [Abstract][Full Text] [Related]
4. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056 [TBL] [Abstract][Full Text] [Related]
5. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697 [TBL] [Abstract][Full Text] [Related]
6. Evaluating entrectinib as a treatment option for non-small cell lung cancer. Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Expert Opin Pharmacother; 2020 Nov; 21(16):1935-1942. PubMed ID: 32736487 [TBL] [Abstract][Full Text] [Related]
7. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements. Delgado J; Pean E; Melchiorri D; Migali C; Josephson F; Enzmann H; Pignatti F ESMO Open; 2021 Apr; 6(2):100087. PubMed ID: 33735800 [TBL] [Abstract][Full Text] [Related]
8. Entrectinib: First Global Approval. Al-Salama ZT; Keam SJ Drugs; 2019 Sep; 79(13):1477-1483. PubMed ID: 31372957 [TBL] [Abstract][Full Text] [Related]
9. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD; Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors. Mercier F; Djebli N; González-Sales M; Jaminion F; Meneses-Lorente G Cancer Chemother Pharmacol; 2022 Mar; 89(3):363-372. PubMed ID: 35118559 [TBL] [Abstract][Full Text] [Related]
11. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Rolfo C; Ruiz R; Giovannetti E; Gil-Bazo I; Russo A; Passiglia F; Giallombardo M; Peeters M; Raez L Expert Opin Investig Drugs; 2015; 24(11):1493-500. PubMed ID: 26457764 [TBL] [Abstract][Full Text] [Related]
12. Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors. Osman HM; Tuncbilek M Curr Med Chem; 2022; 29(15):2602-2616. PubMed ID: 34521321 [TBL] [Abstract][Full Text] [Related]
13. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Katayama R; Gong B; Togashi N; Miyamoto M; Kiga M; Iwasaki S; Kamai Y; Tominaga Y; Takeda Y; Kagoshima Y; Shimizu Y; Seto Y; Oh-Hara T; Koike S; Nakao N; Hanzawa H; Watanabe K; Yoda S; Yanagitani N; Hata AN; Shaw AT; Nishio M; Fujita N; Isoyama T Nat Commun; 2019 Aug; 10(1):3604. PubMed ID: 31399568 [TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. Paz-Ares L; Barlesi F; Siena S; Ahn MJ; Drilon A; Conley A; Rolfo C; Wolf J; Seto T; Doebele R; Kapre A; Chen D; McCallum S; Osborne S; Demetri G ESMO Open; 2021 Jun; 6(3):100113. PubMed ID: 33930659 [TBL] [Abstract][Full Text] [Related]
15. Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date. Araujo JM; Gomez AC; Pinto JA; Rolfo C; Raez LE Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):192-198. PubMed ID: 33290717 [TBL] [Abstract][Full Text] [Related]
16. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381 [TBL] [Abstract][Full Text] [Related]
17. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Desai AV; Robinson GW; Gauvain K; Basu EM; Macy ME; Maese L; Whipple NS; Sabnis AJ; Foster JH; Shusterman S; Yoon J; Weiss BD; Abdelbaki MS; Armstrong AE; Cash T; Pratilas CA; Corradini N; Marshall LV; Farid-Kapadia M; Chohan S; Devlin C; Meneses-Lorente G; Cardenas A; Hutchinson KE; Bergthold G; Caron H; Chow Maneval E; Gajjar A; Fox E Neuro Oncol; 2022 Oct; 24(10):1776-1789. PubMed ID: 35395680 [TBL] [Abstract][Full Text] [Related]
18. Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer. Desilets A; Repetto M; Drilon A Clin Transl Med; 2024 Oct; 14(10):e70017. PubMed ID: 39402859 [TBL] [Abstract][Full Text] [Related]
19. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor. Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761 [TBL] [Abstract][Full Text] [Related]
20. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Ardini E; Menichincheri M; Banfi P; Bosotti R; De Ponti C; Pulci R; Ballinari D; Ciomei M; Texido G; Degrassi A; Avanzi N; Amboldi N; Saccardo MB; Casero D; Orsini P; Bandiera T; Mologni L; Anderson D; Wei G; Harris J; Vernier JM; Li G; Felder E; Donati D; Isacchi A; Pesenti E; Magnaghi P; Galvani A Mol Cancer Ther; 2016 Apr; 15(4):628-39. PubMed ID: 26939704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]